uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
Vise andre og tillknytning
2014 (engelsk)Inngår i: Advances in Therapy, ISSN 0741-238X, E-ISSN 1865-8652, Vol. 31, nr 4, s. 375-391Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum sunscreen with high ultraviolet (UV) A and UVB protection. These measures can help optimize AE management, which is key to maintaining patients on an optimal treatment dose.

sted, utgiver, år, opplag, sider
2014. Vol. 31, nr 4, s. 375-391
Emneord [en]
Adverse event management, Expert opinion, Gastrointestinal events, Idiopathic pulmonary fibrosis, Photosensitivity, Pirfenidone, Respiratory, Safety, Skin-related events
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-228237DOI: 10.1007/s12325-014-0112-1ISI: 000335309800001OAI: oai:DiVA.org:uu-228237DiVA, id: diva2:733282
Merknad

Correction in: Advances in Therapy, Volume 31, Issue 5, pp 575-576 , doi: 10.1007/s12325-014-0118-8

Tilgjengelig fra: 2014-07-08 Laget: 2014-07-08 Sist oppdatert: 2018-01-11bibliografisk kontrollert

Open Access i DiVA

fulltext(1272 kB)153 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1272 kBChecksum SHA-512
48245643cadbb8281398c433732d90adc79990cdd375cd27efecb73e4bbaa2a45d1b4960bad1b18619b7123d56e5a96bd0c1a23976d5f0b126296f939cd7fed0
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekst

Personposter BETA

Hellström, Per M.

Søk i DiVA

Av forfatter/redaktør
Hellström, Per M.
Av organisasjonen
I samme tidsskrift
Advances in Therapy

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 153 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 541 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf